Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9
Introduction
Nilofer S Azad
Johns Hopkins Sidney Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy
Ryan J. Sullivan
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Discussant
Stephen B Baylin
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy
Solange Peters
Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Discussant
David R Gandara
UC Davis Comprehensive Cancer Ctr., Sacramento, CA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies
Julius Strauss
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Discussant
Maura L Gillison
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies
Hyun Cheol Chung
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Discussant
Taofeek Kunle Owonikoko
Emory University, Atlanta, GA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9